Non-Small Cell Lung Cancer (NSCLC) Clinical Trials 2024: EMA, - openPR.com
DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.
Related Clinical Trials
Reference News
DelveInsight's 'Non-Small-Cell Lung Cancer Pipeline Insight 2024' covers 135+ companies and 150+ pipeline drugs, highlighting key players like BridgeBio Pharma, Daiichi Sankyo, and Merck. Prominent therapies include Trastuzumab deruxtecan, DS-1062a, and Pembrolizumab. Recent studies by Merck, AstraZeneca, and Gilead focus on Phase 3 trials for V940, Durvalumab, and Zimberelimab, respectively.
DelveInsight's 'HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2024' covers 5+ companies and 5+ pipeline drugs, including clinical and nonclinical profiles, therapeutic assessments by product type, stage, route of administration, and molecule type, highlighting inactive products. Key companies include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, and Spectrum Pharmaceuticals Inc., with promising therapies like Trastuzumab deruxtecan and Poziotinib.